U.S. Markets open in 9 hrs 23 mins

Cellular Biomedicine Group to Present at the 2019 Cantor Global Healthcare Conference

NEW YORK and SHANGHAI, Oct. 1, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that Derrick Li, Head of Strategy for the Company, will present at Cantor Fitzgerald's 2019 Global Healthcare Conference to be held at the InterContinental New York Barclay Hotel in New York, NY on Thursday, October 3, 2019 at 3:00pm ET.

Cellular Biomedicine Group logo (PRNewsfoto/Cellular Biomedicine Group)

For more information about the conference, or to schedule a one-on-one meeting with CBMG management, please contact KCSA Strategic Communications at cellbiomed@kcsa.com, your Cantor representative directly, or send an email to corporateaccess@cantor.com.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. It conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a "Joint Laboratory of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy Technology Innovation and Application Center" with Thermo Fisher Scientific, which partnerships focus on improving manufacturing processes for cell therapies. CBMG currently has ongoing CAR-T Phase I clinical trials in China. The China NMPA (formerly CFDA) accepted the Company's IND application for a Phase II trial for AlloJoin®, CBMG's "Off-the-Shelf" allogeneic haMPC therapy for the treatment of Knee Osteoarthritis (KOA), and has accepted the Company's IND application for a Phase II trial for ReJoin® autologous haMPC therapy for the treatment of KOA. CBMG is included in the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.

For more information, please contact:

Company Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com

Investor Contact:
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1254 / 212-896-1267
Email: cellbiomed@kcsa.com

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-to-present-at-the-2019-cantor-global-healthcare-conference-300929072.html